- Home
- BIIB vs PUK Comparison
BIIB vs PUK Comparison
Compare BIIB & PUK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PUK
- Stock Information
- Founded
- BIIB 1978
- PUK 1848
- Country
- BIIB United States
- PUK Hong Kong
- Employees
- BIIB N/A
- PUK N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PUK Life Insurance
- Sector
- BIIB Health Care
- PUK Finance
- Exchange
- BIIB Nasdaq
- PUK Nasdaq
- Market Cap
- BIIB 25.1B
- PUK N/A
- IPO Year
- BIIB 1991
- PUK 1990
- Fundamental
- Price
- BIIB $149.90
- PUK $16.14
- Analyst Decision
- BIIB Buy
- PUK
- Analyst Count
- BIIB 26
- PUK 0
- Target Price
- BIIB $248.00
- PUK N/A
- AVG Volume (30 Days)
- BIIB 1.5M
- PUK 762.4K
- Earning Date
- BIIB 02-11-2025
- PUK 08-28-2024
- Dividend Yield
- BIIB N/A
- PUK 2.61%
- EPS Growth
- BIIB 10.05
- PUK N/A
- EPS
- BIIB 11.06
- PUK 0.32
- Revenue
- BIIB $9,607,500,000.00
- PUK $10,944,000,000.00
- Revenue This Year
- BIIB N/A
- PUK N/A
- Revenue Next Year
- BIIB N/A
- PUK $11.71
- P/E Ratio
- BIIB $13.55
- PUK $24.03
- Revenue Growth
- BIIB N/A
- PUK N/A
- 52 Week Low
- BIIB $145.07
- PUK $15.11
- 52 Week High
- BIIB $268.30
- PUK $22.52
- Technical
- Relative Strength Index (RSI)
- BIIB 35.04
- PUK 46.98
- Support Level
- BIIB $145.07
- PUK $15.57
- Resistance Level
- BIIB $149.92
- PUK $17.27
- Average True Range (ATR)
- BIIB 3.71
- PUK 0.26
- MACD
- BIIB 0.26
- PUK -0.04
- Stochastic Oscillator
- BIIB 30.65
- PUK 30.30
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.